EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Evaluation of Dupilumab in Patients With Bullous Pemphigoid

Liuqi Zhao, Qijun Wang, Guirong Liang, Yuxi Zhou, Nam Yiu, Baoqi Yang, Guiying Zhang, Wei Li, Suying Feng, Panpan Shang, Xixue Chen, Xuejun Zhu und 3 weitere

JAMA Dermatology · 01.09.2023 · 159 (9) · 953

DOI: 10.1001/jamadermatol.2023.2428 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Dermatology, erschienen am 01.09.2023. Verfasst von Liuqi Zhao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Autoimmune Diseases. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Dupilumab is a theoretically novel therapy for bullous pemphigoid (BP). However, its effectiveness and safety have yet to be confirmed in a large-scale study.

Objective

To assess the efficacy and safety of dupilumab in patients with BP and evaluate factors that potentially affect short-term and long-term outcomes. Design, Setting, and Participants A retrospective cohort study was conducted from January 1, 2021, to July 31, 2022. The median (IQR) follow-up period was 24.6 (11.5-38.4) weeks. This multicenter study was performed in 6 dermatology departments of the National Autoimmune Bullous Diseases Cooperative Group of China. Adult patients with BP that received 300 mg of dupilumab every 2 weeks following an initial dose of 600 mg were included. Patients were eligible if they had a clinical presentation of BP combined with immunological or pathological evidence. Patients with drug-induced BP, with less than 4 weeks of follow-up, and who received dupilumab or any other biologics within 6 months were excluded. Main Outcomes and Measures The primary outcome was the proportion of patients who achieved disease control within 4 weeks. Disease control was defined as the absence of new lesions and pruritus, combined with the healing of existing lesions. Complete remission rates, relapse rates, changes in Bullous Pemphigoid Disease Area Index (BPDAI) scores, itching numerical rating scale (NRS) scores, laboratory results within 64 weeks, and adverse events (AEs) were also assessed.

Results

Among 146 patients (median [IQR] age, 73 [64-85] years; 86 [58.9%] male patients) included in the study, 127 (87.0%) patients achieved disease control within 4 weeks, with a median (IQR) time of 14 (7-14) days. A total of 52 (35.6%) patients achieved complete remission, and 13 (8.9%) patients relapsed during the observation period. The complete remission rate and cumulative relapse rate at week 64 were 62.5% (5 of 8) and 30.9%, respectively. There was rapid and sustained improvement in clinical indicators and laboratory examination results after dupilumab treatment, including BPDAI scores, itching NRS scores, serum anti-BP180 and anti-BP230 antibodies, total IgE levels, and eosinophil count. Of these 146 patients, 107 (73.3%) did not report any AEs. The most common AEs were infections and eosinophilia. Serum anti-BP180 antibody levels of greater than 50 relative units (RU)/mL (OR, 3.63; 95% CI, 0.97-12.61; P = .045) were associated with 4-week disease control, and male patients were more likely to relapse (HR, 10.97; 95% CI, 1.42-84.92; P = .02). Conclusions and Relevance In this retrospective cohort study, dupilumab treatment was associated with improved clinical symptoms in patients with BP. The safety profile was favorable, although concurrent infection and eosinophilia might pose potential concerns. This study suggests that patients with anti-BP180 antibody levels of at least 50 RU/mL and female sex may respond better.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousAutoimmune DiseasesAdultHumansMaleFemaleAgedRetrospective StudiesPruritusAutoantibodiesAutoantigensRecurrenceAntibodies, Monoclonal, Humanized

Substanzen

AutoantibodiesAutoantigensdupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Peking University First Hospital, Beijing, China.
  • National Autoimmune Bullous Disease Cooperative Group, China.
  • National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
  • Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.
  • Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China.

Zitieren

APA

Zhao, L., Wang, Q., Liang, G., Zhou, Y., Yiu, N., Yang, B., Zhang, G., Li, W., Feng, S., Shang, P., Chen, X., Zhu, X., Zheng, J., Pan, M., & Wang, M. (2023). Evaluation of Dupilumab in Patients With Bullous Pemphigoid. JAMA Dermatology, 159(9), 953. https://doi.org/10.1001/jamadermatol.2023.2428

Vancouver

Zhao L, Wang Q, Liang G, Zhou Y, Yiu N, Yang B, et al. Evaluation of Dupilumab in Patients With Bullous Pemphigoid. JAMA Dermatology. 2023;159(9):953. doi:10.1001/jamadermatol.2023.2428

BibTeX
@article{Zhao2023,
  author = {Zhao, Liuqi and Wang, Qijun and Liang, Guirong and Zhou, Yuxi and Yiu, Nam and Yang, Baoqi and Zhang, Guiying and Li, Wei and Feng, Suying and Shang, Panpan and Chen, Xixue and Zhu, Xuejun and Zheng, Jie and Pan, Meng and Wang, Mingyue},
  title = {Evaluation of Dupilumab in Patients With Bullous Pemphigoid},
  journal = {JAMA Dermatology},
  year = {2023},
  volume = {159},
  number = {9},
  pages = {953},
  doi = {10.1001/jamadermatol.2023.2428}
}
Kostenlos starten →